Are Analysts Bullish about Valeant Pharmaceuticals Interna (NYSE:VRX) after last week?

October 11, 2018 - By Marguerite Chambers

Valeant Pharmaceuticals Interna (NYSE:VRX) LogoInvestors sentiment decreased to 0.66 in 2018 Q2. Its down 0.40, from 1.06 in 2018Q1. It dived, as 58 investors sold Valeant Pharmaceuticals Interna shares while 85 reduced holdings. 39 funds opened positions while 56 raised stakes. 142.12 million shares or 15.06% less from 167.32 million shares in 2018Q1 were reported.
Assetmark Incorporated reported 0% stake. Credit Suisse Ag holds 0.02% or 966,792 shares. 401,000 were reported by Miracle Mile Advisors Lc. Nelson Van Denburg And Campbell Wealth Mngmt Group Lc invested 0% in Valeant Pharmaceuticals Interna (NYSE:VRX). Moreover, Public Sector Pension Invest Board has 0.05% invested in Valeant Pharmaceuticals Interna (NYSE:VRX). Goldman Sachs Gru holds 2.67M shares. Captrust Financial owns 2,000 shares. 510 are held by Sei. Prudential Public Limited Co owns 433,082 shares. Rbf Ltd, California-based fund reported 202,600 shares. Alliancebernstein L P invested in 182,411 shares or 0% of the stock. Northern accumulated 0% or 173,663 shares. Wellington Management Gp Llp invested in 297,608 shares or 0% of the stock. 900 are owned by Wg Shaheen Assoc Dba Whitney. Bb&T Ltd Co has 0.01% invested in Valeant Pharmaceuticals Interna (NYSE:VRX).

Since May 15, 2018, it had 5 buys, and 0 selling transactions for $4.44 million activity. Shares for $3.00M were bought by DE SCHUTTER RICHARD U. PAPA JOSEPH C bought $669,600 worth of Valeant Pharmaceuticals Interna (NYSE:VRX) on Friday, September 14.

Valeant Pharmaceuticals Interna (NYSE:VRX) Ratings Coverage

Among 8 analysts covering Valeant Pharma (NYSE:VRX), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Valeant Pharma had 14 analyst reports since May 2, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Hold” on Tuesday, June 5. The firm has “Hold” rating by RBC Capital Markets given on Thursday, May 10. The firm has “Hold” rating by H.C. Wainwright given on Monday, May 7. The firm has “Hold” rating given on Friday, June 22 by TD Securities. The rating was maintained by BTIG Research with “Hold” on Tuesday, June 19. The stock of Valeant Pharmaceuticals Interna (NYSE:VRX) has “Hold” rating given on Wednesday, June 27 by H.C. Wainwright. As per Wednesday, May 2, the company rating was maintained by RBC Capital Markets. The firm has “Hold” rating by H.C. Wainwright given on Tuesday, June 19. Barclays Capital upgraded the stock to “Overweight” rating in Wednesday, June 6 report. The rating was maintained by Mizuho with “Buy” on Monday, June 18. Below is a list of Valeant Pharmaceuticals Interna (NYSE:VRX) latest ratings and price target changes.

27/06/2018 Broker: H.C. Wainwright Rating: Hold New Target: $20.0000 Maintain
22/06/2018 Broker: TD Securities Old Rating: Buy New Rating: Hold Downgrade
19/06/2018 Broker: BTIG Research Rating: Hold Maintain
19/06/2018 Broker: H.C. Wainwright Rating: Hold New Target: $20.0000 Maintain
18/06/2018 Broker: Mizuho Rating: Buy New Target: $27.0000 Maintain
06/06/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Overweight Old Target: $34 Upgrade
05/06/2018 Broker: H.C. Wainwright Rating: Hold New Target: $20.0000 Maintain
15/05/2018 Broker: Mizuho Rating: Buy Upgrade
15/05/2018 Broker: Inc. Rating: Mizuho
10/05/2018 Broker: RBC Capital Markets Rating: Hold New Target: $19.0000 Maintain

The stock increased 4.51% or $0.78 during the last trading session, reaching $18.06. About 4.06 million shares traded or Infinity% up from the average. Valeant Pharmaceuticals Interna (NYSE:VRX) has 0.00% since October 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It currently has negative earnings. Diversified Products.

Another recent and important Valeant Pharmaceuticals Interna (NYSE:VRX) news was published by Investorplace.com which published an article titled: “Pyxus Stock Could Backfire Over the Longer Term” on October 10, 2018.

Valeant Pharmaceuticals Interna (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>